References

Azran C, Wolk O, Zur M Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev.. 2016; 17:(11)1050-66 https://doi.org/10.1111/obr.12434

Azran C, Langguth P, Dahan A. Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass. Surg Obes Relat Dis.. 2017; 13:(7)1245-7 https://doi.org/10.1016/j.soard.2017.03.003

Azran C, Porat D, Fine-Shamir N Oral levothyroxine therapy postbariatric surgery: biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis.. 2019; 15:(2)333-41 https://doi.org/10.1016/j.soard.2019.01.001

Bland CM, Quidley AM, Love BL Long-term pharmacotherapy considerations in the bariatric surgery patient. Am J Health Syst Pharm.. 2016; 73:(16)1230-42 https://doi.org/10.2146/ajhp151062

British National Formulary 77.London: Royal Pharmaceutical Society; 2018

Chan LN, Lin YS, Tay-Sontheimer JC Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates. Pharmacotherapy. 2015; 35:(4)361-9 https://doi.org/10.1002/phar.1560

Darwich AS, Pade D, Ammori BJ A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol.. 2012; 64:(7)1008-24 https://doi.org/10.1111/j.2042-7158.2012.01538.x

Ettleson MD, Lager CJ, Kraftson AT Roux-en-Y gastric bypass versus sleeve gastrectomy: risks and benefits. Minerva Chir.. 2017; 72:(6)505-19

Fallahi P, Ferrari SM, Camastra S TSH normalization in bariatric surgery patients after the switch from l-thyroxine in tablet to an oral liquid formulation. Obes Surg.. 2017; 27:(1)78-82 https://doi.org/10.1007/s11695-016-2247-4

Gesquiere I, Hens B, Van der Schueren B Drug disposition before and after gastric bypass: fenofibrate and posaconazole. Br J Clin Pharmacol.. 2016; 82:(5)1325-32 https://doi.org/10.1111/bcp.13054

Greenblatt HK, Greenblatt DJ. Altered drug disposition following bariatric surgery: a research challenge. Clin Pharmacokinet.. 2015; 54:(6)573-9 https://doi.org/10.1007/s40262-015-0259-1

Guller U, Klein LV, Hagen JA. Safety and effectiveness of bariatric surgery: Roux-en-Y gastric bypass is superior to gastric banding in the management of morbidly obese patients. Patient Saf Surg.. 2009; 3:(1) https://doi.org/10.1186/1754-9493-3-10

Gómez-Ramírez S, Brilli E, Tarantino G, Muñoz M. Sucrosomial® iron: a new generation for improving oral supplementation. Pharmaceuticals. 2018; 11:(4) https://doi.org/10.3390/ph11040097

Hommel C, Delgrange E. Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation?. Acta Clin Belg.. 2017; 72:(1)72-5 https://doi.org/10.1080/17843286.2016.1196861

Ludvigsson M, Haenni A. Methylphenidate toxicity after Roux-en-Y gastric bypass. Surg Obes Relat Dis.. 2016; 12:e55-7

Krieger CA, Cunningham JL, Reid JM Comparison of bioavailability of single-dose extended-release venlafaxine capsules in obese patients before and after gastric bypass surgery. Pharmacotherapy. 2017; 37:(11)1374-1382 https://doi.org/10.1002/phar.2022

Macgregor AMC, Boggs L. Drug disposition in obesity and following bariatric surgery: a literature review. Obes Surg.. 1996; 6:(1)17-27 https://doi.org/10.1381/096089296765557222

Martin KA, Lee CR, Farrell TM, Moll S. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. Am J Med.. 2017; 130:(5)517-24 https://doi.org/10.1016/j.amjmed.2016.12.033

Mischler RA, Armah SM, Craig BA Comparison of oral iron supplement formulations for normalization of iron status following Roux-en-Y gastric bypass surgery: a randomized trial. Obes Surg.. 2018; 28:(2)369-77 https://doi.org/10.1007/s11695-017-2858-4

Mitchell JE, Crosby R, de Zwaan M Possible risk factors for increased suicide following bariatric surgery. Obesity (Silver Spring). 2013; 21:(4)665-72 https://doi.org/10.1002/oby.20066

Muzard L, Alvarez JC, Gbedo C Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Obes Res Clin Pract.. 2017; 11:(1)108-13 https://doi.org/10.1016/j.orcp.2016.06.004

Statistics on Obesity, Physical Activity and Diet.: National Statistics; 2017

O'Kane M, Pinkney J, Aasheim ET BOMSS guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery.London: British Obesity and Metabolic Surgery Society; 2014

Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev.. 2010; 11:(1)41-50 https://doi.org/10.1111/j.1467-789X.2009.00614.x

Padwal RS, Ben-Eltriki M, Wang X Effect of gastric bypass surgery on azithromycin oral bioavailability. J Antimicrob Chemother.. 2012; 67:(9)2203-6 https://doi.org/10.1093/jac/dks177

Pirola I, Formenti AM, Gandossi E Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes Surg.. 2013; 23:(9)1493-6 https://doi.org/10.1007/s11695-013-1015-y

Ring Madsen L, Espersen R, Rejnmark L, Richelsen B. Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux-en-Y gastric bypass. A double-blinded, randomized trial. Clin Endocrinol (Oxf). 2018; 89:(6)734-41 https://doi.org/10.1111/cen.13836

Rocha MBS, De Nucci G, Lemos FN Impact of bariatric surgery on the pharmacokinetics parameters of amoxicillin. Obes Surg.. 2019; 29:(3)917-27 https://doi.org/10.1007/s11695-018-3591-3

Sawaya RA, Jaffe J, Friedenberg L, Friedenberg FK. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab.. 2012; 13:(9)1345-55 https://doi.org/10.2174/138920012803341339

Schlatter J. Oral contraceptives after bariatric surgery. Obes Facts. 2017; 10:(2)118-26 https://doi.org/10.1159/000449508

Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005; 46:(3)250-3 https://doi.org/10.1176/appi.psy.46.3.250

Stein J, Stier C, Raab H, Weiner R. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther.. 2014; 40:(6)582-609 https://doi.org/10.1111/apt.12872

Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Pract.. 2013; 28:(4)429-36 https://doi.org/10.1177/0884533613490740

Yska JP, van der Linde S, Tapper VV Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg.. 2013; 23:(6)819-25 https://doi.org/10.1007/s11695-013-0882-6

Yska JP, van der Meer DH, Dreijer AR Influence of bariatric surgery on the use of medication. Eur J Clin Pharmacol.. 2016a; 72:(2)203-9 https://doi.org/10.1007/s00228-015-1971-3

Yska JP, Gertsen S, Flapper G NSAID use after bariatric surgery: a randomized controlled intervention study. Obes Surg.. 2016b; 26:(12)2880-5 https://doi.org/10.1007/s11695-016-2218-9

Zhang C, Yuan Y, Qiu C, Zhang W. A meta-analysis of 2-year effect after surgery: laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for morbid obesity and diabetes mellitus. Obes Surg.. 2014; 24:(9)1528-35 https://doi.org/10.1007/s11695-014-1303-1

Prescribing challenges following bariatric surgery

02 September 2019
Volume 1 · Issue 9

Abstract

Obesity is an increasing problem in the UK, with over half of the population being overweight or obese. The use of gastric surgery is increasing, with a 5% increase in 2016/17 compared to 2015/16. However, little is known about ideal drug formulations after bariatric surgery. An exploratory literature search of research databases was carried out to address this. The authors found that there was a dearth of high-quality primary studies available, with many studies using low numbers of participants. The major finding was of the need for increased vigilance and monitoring of patients after surgery.

The statistics surrounding obesity in the UK are concerning. The prevalence of people who are overweight or obese was 57% for women and 66% for men in 2016 (NHS Digital, 2017). The prevalence of obesity alone has increased from 15% of the population in 1993 to 27% by 2015 (NHS Digital, 2017). This is an increasing trend worldwide, with the UK currently having the dubious value of being near the top of the league table for obesity prevalence; ranked sixth out of 34 countries (NHS Digital, 2018). The same statistics reveal that 617 000 admissions to hospital in 2016/17 were related to obesity, an increase of 18% on the previous year. There was a 5% increase in admissions for bariatric surgery in 2016/17 compared to 2015/16 from 6000 to 6760, although the total number has not reached the peak seen in 2011/12 (NHS Digital, 2018).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month